Drug Profile
1018 ISS
Alternative Names: First generation 1018 ISS - Dynavax; ISS 1018; ISS DNA; ISS1; ISS2Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Developer Dana-Farber Cancer Institute; Dynavax Technologies
- Class DNA; Oligonucleotides
- Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Allergic asthma
- Discontinued Colorectal cancer; Human papillomavirus infections; Non-Hodgkin's lymphoma
Most Recent Events
- 16 Apr 2008 Discontinued - Preclinical for Human papillomavirus infections in USA (unspecified route)
- 08 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the adverse events section
- 30 Nov 2006 Phase-I clinical trials in Colorectal cancer (combination therapy, second-line therapy or greater) in USA (SC) (NCT00403052)